Zentiva

This page shows the latest Zentiva news and features for those working in and with pharma, biotech and healthcare.

Sanofi sells European generics to Advent for $2.4bn

Sanofi has been looking to divest the Zentiva generics unit since 2016 as part of restructuring the business under chief executive Olivier Brandicourt, who said: “Transferring this business to Advent is ... Sanofi bought the foundations of its European

Latest news

Ten new medicines recommended in Europe

Duloxetine Zentiva (duloxetine) - a copycat of Lilly's Cymbalta - for the treatment of major depressive disorder, diabetic peripheral neuropathic pain and generalised anxiety disorder, also saw a nod from the EMA.
Three cancer immunotherapies amongst new CHMP approvals

Finally, two generic medicines gained positive opinions: Bortezomib Accord (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma and Pregabalin Zentiva (pregabalin) for the treatment of epilepsy and generalised
Orphan drugs in latest CHMP recommendations

Completing the positive opinions were two new informed consent applications: Sevelamer carbonate Zentiva (sevelamer) from Genzyme for the control of hyperphosphataemia in adults receiving haemodialysis or peritoneal dialysis and Rasagiline
A look back at Sanofi's merger with Synthélabo

Following this dramatic move, Sanofi continued its expansion, including high profile acquisitions, such as Czech Republic-based Zentiva in 2009 to give the company a foothold in Eastern Europe, and the
Sanofi SVP to become president and CEO of Teva Europe

Prior to his current position at Sanofi, Koremans was CEO at Zentiva, the European generics business for Sanofi.

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest appointments

Karim Husny moves from Omega Pharma to Alliance Pharmaceuticals

He brings experience in over the counter and consumer healthcare having worked at several European pharmaceutical firms, including Laboratoire de la Mer, Pfizer and Sanofi's Zentiva business.
Watson selects global generics management team

Ramneborn has more than 20 years' experience in the pharmaceutical industry and joined Actavis from Zentiva, where he was vice president and a member of the board of directors since 2003.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Account Manager – Med Comms – London: Salary TBC

Senior Account Manager – Med Comms – Kent: Salary TBC

Senior Account Manager / Account Director: Great salary and bebefits

Project Manager, Medical Communications, London: Excellent Salary

Group Account Director, Healthcare Brand Communications, London: Excellent Package

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Scientific Director: Great salary and bebefits

Editor – Medical Education Agency – Bucks: Salary TBC

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Medical Writer, e-learning/ training, London: Excellent Salary

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Medical Writer: Great salary and benefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Editorial Director – Medical Education – Oxford: Negotiable

Senior Medical Writer: Great salary and bebefits

Project Manager, Medical Communications, Oxford: Excellent Salary

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Subscribe to our email news alerts

PMHub

Add my company

Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...